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Graphical Abstract 
 
 
 
Cationic tricyclic photosensitisers such as the phenothiazinium S137 (shown) are 
highly effective bacterial killers when activated by the correct wavelength light.  
Microbial killing by reactive oxygen species such as singlet oxygen (1O2) is 
unaffected by conventional antimicrobial resistance. 
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Abstract 
Despite the preponderance of literature pertaining to photosensitisers based on the 
porphyrin system, many other chemical classes are available with similar or improved 
characteristics and potential for use in photodynamic medicine.  Several of these 
classes are based on small, tricyclic, heteroaromatic chromophores, often originally 
developed from textile dyes or biological stains.  The latter classification is useful in 
providing a basis for biological uptake and antimicrobial activity. 
The current review covers the chemistry and photoantimicrobial applications of 
established and novel cationic bisamino derivatives of the acridine, phenazine, 
phenoxazine, phenothiazine and xanthene systems and related compounds.  The range 
covered is considerable and demonstrates photodynamic performance to rival the 
porphyrin class.  In addition, the chemical synthesis of new analogues of lead 
compounds such as methylene blue or acridine orange is relatively straightforward 
and inexpensive, and compound series with varying physicochemical profiles have 
been produced for structure-activity studies in order to furnish improved 
photosensitisers for clinical trialling. 
 
Keywords: acridine, benzologue, chalcogens, phenazine, phenoxazine, 
phenoselenazine, phenothiazine, rosamine, photosensitiser 
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1. History 
Dyes and pigments are very important in the modern world – from the colouration of 
the human environment with paints, plastics and textiles, to dyed clothing and food 
colours.  The significance of the chemicals used in the various processes leading to 
colouration is mostly taken for granted, if appreciated at all.  Similarly, the non-
traditional, high-technology use of dye molecules has applications in electronics, 
light-emitting diodes, photovoltaics, lasers and biosensors, again normally 
unappreciated by the end user.  The application of dyes as biological stains remains 
highly important in the establishment of infectious disease aetiology via the 
ubiquitous use of the Gram stain, and there are many examples of established stains in 
histochemistry and histopathology.1 
 
Another aspect of synthetic dye usage is their part in the development of modern 
drugs.  The growth of the pharmaceutical industry can be traced back to the initial 
essays in aniline dye synthesis in the middle part of the nineteenth century, following 
Perkin’s accidental synthesis of the phenazine derivative, mauveine in 1856.  The 
oxidative reagents used with the various available (but impure) anilines led to the 
production of a range of colours due to the oxidised heteroaromatic chromophores 
produced, often involving sulphur as well as nitrogen.  Among the earliest 
chromophores thus obtained were oxidised phenothiazines (phenothiaziniums), 
methylene blue and thionine being first reported in 1876.2,3  Early research into the 
use of such compounds to differentiate cells by Koch, Ehrlich and others eventually 
led to selective toxicity studies and, in turn, to chemotherapy.  Here, dyes which were 
employed directly as drugs – e.g. the aminoacridines, the azo dye Prontosil and 
methylene blue itself, became lead compounds for future drug development.4 
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2. Photosensitisation 
 
Photosensitisers – as opposed to conventional dyes – are light-absorbing molecules 
which are able to populate the excited electronic triplet state (*T1) significantly, thus 
allowing electron transfer reactions with, or energy transfer to, molecules – typically 
oxygen - in the environment.  The basis of cytotoxic photosensitisation is the 
generation of reactive oxygen species in situ.  The superoxide anion, hydroxyl radical 
and peroxides are produced via electron transfer and singlet oxygen via energy 
transfer. (Figure 1). 
 
 
 
Figure 1.  Excitation/relaxation pathways involved in photosensitisation.  Key: S0 – 
singlet electronic ground state of photosensitiser; *S1 - singlet excited state; *T1 - 
triplet excited state; h - energy of absorbed photon; IC – internal conversion; F - 
fluorescence; P - phosphorescence; ISC – inter-system crossing. 
 
Tricyclic lead compounds, such as the phenothiazinium derivative methylene blue, 
produce singlet oxygen efficiently, but it is also possible to design analogue molecules 
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based on the enhancement of factors supporting this – e.g. heavy atom inclusion 
(q.v.). 
 
For the triplet excited state to be sufficiently populated, a relatively long-lived excited 
singlet state allowing efficient conversion from *S1→*T1 is essential.  Deactivation of 
the *S1 state may occur radiatively (fluorescence) and non-radiatively (internal 
conversion), as with conventional dye molecules. 
 
Stabilisation of the *T1 state itself by the inclusion of atoms of a high atomic number 
is due to large associated spin-orbital coupling constants and is known as the “heavy 
atom” effect.  The peripheral inclusion of bromine or iodine in the chromophore, or 
(usually) of sulphur or selenium as ring heteroatoms is common modern practice in 
the maximisation of singlet oxygen production. 
 
 
2.1 Dyes as Photoantimicrobials 
Raab’s initial reporting of the photosensitising action of dyes in 1900 was based on 
the simple nitrogen tricyclic molecule acridine and the xanthene derivative eosin,5 the 
latter also featuring in mammalian cell (anticancer) studies within a few years.6  
Although various discoveries were made with synthetic dyes throughout the next sixty 
years, the proper development of photodynamic therapy (PDT) as a cancer treatment, 
beginning in the 1960s,7 was firmly based on naturally-occurring porphyrin 
derivatives, and this remains the case to date, with synthetics constituting something 
of a lower class.  To a certain extent, this is also true in the related field of 
photodynamic antimicrobial chemotherapy (PACT),8 despite the fact that there is far 
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less rationale for the use here of the anionic porphyrins used in cancer PDT.  If PDT 
did not exist, PACT would be firmly based on cationic dyes such as methylene blue 
and the benzo[a]phenoxazine Nile blue.  However, there remains what amounts 
almost to a “porphyrin panacea” approach to all aspects of potential photodynamic 
medicine among a large section of researchers. 
 
The lead compounds for synthetic photosensitisers proposed for use in biomedicine, 
particularly in the area of photoantimicrobials, constitute, in the main, a sub-class of 
established biological stains.  Undoubtedly, methylene blue is premier among these, 
but it is important to recognise that it is not the sine qua non, despite its many medical 
applications in the past.9  Substituting a methylene blue panacea for the porphyrin 
version is equally unsuitable in taking forward photodynamic science or its medical 
applications. 
 
There are many candidate chromophores for novel photosensitisers from the field of 
biological staining, and these underpin the “stain and kill” approach to the 
development of fit-for-purpose photoantimicrobial agents.  Several lead compounds 
may thus be found in the tricyclic cationic class which, due to the large number of 
starting points for photosensitising drug discovery, is the subject of the present work.  
A section of the xanthene class has also been included among the tricyclic cationic 
compounds: the diamino functionality and cationic nature of the pyronin and rosamine 
derivatives offer considerable structural commonality with methylene blue and its 
congeners. 
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In the 21st Century, it is incumbent on scientific researchers to ensure that their work 
is relevant to modern requirements.  Photosensitiser discovery, particularly relating to 
infection control applications, satisfies this criterion since it addresses a serious, often 
fatal, gap in conventional antimicrobial chemotherapy, viz. drug-resistant infection.10 
 
 
2.2 Structures 
The fundamental chemical structure involved in tricyclic cationic chromophores 
consists of a fused, linear, tricyclic arrangement of six-membered aromatic rings, the 
central one containing one – or, more usually, two - heteroatoms.  Traditionally, the 
combination of heteroatoms is N/NR, N/O, and N/S, but this has been extended to 
combinations of nitrogen with the lower period, Group VI atom selenium, and also to 
the CH/N, RCH/O, RCH/S etc. couples, in order to encompass the acridine, pyronine 
and rosamine photosensitisers (Table 1). 
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Class X Y 
Acridinium CR NR 
Xanthylium (Pyronin, Rosamine) CR O 
Thioxanthylium CR S 
Selenoxanthylium CR Se 
Telluroxanthylium CR Te 
Phenazinium N NR 
Phenoxazinium N O 
Phenothiazinium N S 
Phenoselenazinium N Se 
 
Table 1.  Structures of tricyclic photosensitiser chromophores (R = H, alkyl, aryl, 
heteroaryl) 
 
 
 
Figure 2.  General azinium-type structures, showing the delocalisation of cationic 
charge.  X/Y = CH/NR; RCH/O; RCH/S; RCH/Se; RCH/Te; N/NR; N/O; N/S; N/Se. 
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The representative structures given in Table 1 provide an idea of general molecular 
similarity, although it should be remembered that the different X/Y atomic 
combinations govern the electron density and distribution of the resulting delocalised 
chromophore (Figure 2), thus explaining some of the varying activities among 
representative examples, this being of particular relevance to photosensitising 
capability.  On a more obvious note, this variation in electron density/distribution may 
be visibly observed in solution colour.  For example, acridine orange and methylene 
blue are identical structures save for the central chromophoric heteroatoms, CH/N and 
N/S respectively.  This can also be observed spectrophotometrically for direct 
phenoxazinium and phenothiazinium analogues (i.e. N/O → N/S), usually 
demonstrating a bathochromic shift of max of ca. 20 nm. 
 
 
2.3. Photosensitising activities 
Among research groups involved in new photosensitiser development there has been 
considerable effort committed to measuring the reactive oxygen species (ROS) 
generation of synthesised candidates as one of the necessary performance indicators.  
Usually this consists of mixing the candidate with a quencher, illuminating and 
measuring the decay of the latter spectrophotometrically.  Conversely, singlet oxygen 
can be measured directly via its phosphorescence (delayed fluorescence) at 1270 
nm.11  However, the generation, or otherwise, of ROS - since this is governed by the 
lifetime of the electronic excited state - depends to a large extent on the molecular 
environment of the photosensitiser.  Thus measurements made in solution may not 
reflect behaviour in the clinical situation.  For example, the production of singlet 
oxygen by methylene blue can be observed in alcoholic solution via the decrease in 
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visible absorption of a quencher such as 1,3-diphenylisobenzofuran or 4-nitroso-N,N-
dimethylaniline.12  Such photosensitising activity depends on the absorption of light 
by the methylene blue molecule.  Similarly, the binding of methylene blue to 
deoxyribonucleic acid (DNA), an important and often cited cellular target, can be 
demonstrated spectrophotometrically, since the max of methylene blue shifts by 
approximately 4 nm.13  This is a clear indication that there has been a change to the -
electron cloud of the molecule, compared to that in the free state in solution.  Since 
the generation of singlet oxygen also depends on electronic transitions in the 
photosensitiser, there is clearly potential for biomolecular binding to influence 
photosensitising activity.  Related molecules, such as the acridines proflavine and 
acridine orange produce no measurable singlet oxygen in the standard 
spectrophotometric test but are excellent cellular photosensitisers.  This may also 
support the preceding argument or indicate an electron transfer/redox mode of action 
(Type I photosensitisation). 
 
Such behaviour merely underlines the fact that the testing of potential photosensitisers 
should be realistic.  A ranking order of photosensitising ability constructed using a 
conventional spectrophotometric assay will, in all likelihood, be completely dissimilar 
to the order of efficiency of photokilling, for example, in a bacterial strain for the 
same series of compounds.  As the intended target is bacterial infection, it thus makes 
more sense to use the relevant biological challenge, rather than the in vitro assay, as a 
principal performance indicator. By similar reasoning, a photosensitiser which is an 
excellent candidate for clinical anticancer PDT may have severe shortcomings in anti-
infective terms. 
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For the tricyclic, heteroaromatic range of photosensitisers, as with other groups, 
efficiency in cell killing depends on structure since, although there are many well-
known examples of biological photosensitisers contained here, there are basic 
structures which are inactive, whether in the in vitro assay or in cell culture.  
However, there is sufficient knowledge of chemistry and structure-function 
relationships to be able to remedy such situations via suitable chromophoric 
substitution patterns, as detailed in the sections below. 
 
 
3. Nucleic acid intercalation and deleterious effects in humans 
 
The planar structure, surface area and cationic charge of the photosensitisers covered 
here provide many examples of potential nucleic acid intercalators – i.e. molecules 
which, because of their geometry and charge, are able to fit between consecutive base-
pairs in the double helical structure of DNA.  As mentioned, this interaction can be 
observed easily using a spectrophotometric approach, since the interaction causes a 
fluctuation in the adjacent molecular electron clouds, leading to absorption 
wavelength shifting.  The importance of a sufficient molecular planar area and 
positive charge in this interaction was ably demonstrated by Albert in the 1940s.14 
 
In terms of photodynamic efficacy, such exquisite targeting of a biomolecule is 
obviously highly appealing.  However, in reality it does not constitute a magic bullet.  
It is true that adding a photosensitiser such as methylene blue to a solution of DNA 
leads to observable intercalation.  Subsequent red-light irradiation of the interacting 
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pair causes oxidative breakdown of the nucleic acid, which is again easily observable 
via HPLC of the resulting mixture, 8-hydroxyguanosine being a major product.15 
Conversely, interaction between cellular DNA and such photosensitisers is a much 
more difficult proposition, the degree of difficulty being in proportion to cellular 
complexity.  Thus intercalation may occur with viruses in media, or in bacterial cells 
in culture, and DNA damage following photodynamic action has been reported.16  
However, nuclear DNA in human cell lines is compartmentalised in the cell nucleus 
and, while there are vital nuclear stains, it is more likely that most of the tricyclic 
cations currently under consideration, if localised in the nucleus, would only do so 
after cell death.  DNA damage in the photosensitised cell requires careful analysis, as 
this may occur indirectly, after critical damage to the cell elsewhere, e.g. in the 
lysosome, followed by relocalisation, as is the case for methylene blue.17 
 
It is equally important to consider this proposition objectively.  Biological stains such 
as methylene blue and acriflavine have been used in medicine and clinical laboratories 
for well over 100 years.  There have been no documented associated cases of cancer.  
A similar argument is possible for the photosensitisers discussed below.  While it is 
imperative to carry out efficacy/safety testing on novel drugs, overall objectivity is 
also essential.  The above-mentioned methylene blue, for example, is clearly safe for 
human use and yet produces a positive Ames (bacterial mutagenicity) test result.18 
 
 
4. Photosensitiser requirements – ‘fit for purpose’ photoantimicrobials 
Regardless of molecular type, there are certain criteria which must be satisfied for 
photosensitisation.  Simply, this is the combination of the target, a photosensitiser 
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molecule, oxygen and light.  Any of the various applications is merely an elaboration 
of this and may be deconstructed to provide problem-solving where required in 
practice.  For example, killing bacteria in planktonic culture (i.e. non-biofilm) using a 
standard photosensitiser such as methylene blue should be a straightforward process.  
This is only useful if relevant information is provided towards a clinical end-point – 
e.g. what is the lowest photosensitiser concentration at which complete bacterial kill is 
achieved?  Equally, it is important that the target is relevant – for example, broad-
spectrum photobactericidal activity cannot be extrapolated merely from demonstrable 
efficacy against the standard Gram-positive organism, Staphylococcus aureus.  The 
resounding failure of the otherwise excellent anionic porphyrin photosensitisers used 
in anticancer PDT has been their absence of activity against Gram-negative bacteria.19 
 
Light absorption by the photoantimicrobial, at its target cell, is an essential part of the 
killing process.  Consequently, anything which diminishes the amount of incident 
light makes the process less efficient.  Thus, light absorption by biomolecules such as 
melanin, haem or cytochromes, known as endogenous absorbers, should be avoided.  
This means that where there is the risk of interaction with such species (e.g. in 
wounds), photoantimicrobials must absorb outside their spectral range, typically at 
longer wavelengths.  This is normally taken as the 630-900 nm region and should 
inform the molecular design of potential photoantimicrobials. 
 
Similarly, the period of illumination required to satisfy microbial kill targets should be 
reasonable with respect to patient treatment.  A period of tens of seconds or a few 
minutes is reasonable.  One of several hours is not. 
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One of the greatest hurdles encountered in moving a drug molecule from bench to 
bedside remains that of human toxicity.  Clearly this has been the main problem in 
developing new clinical photosensitisers, once improved structures have been decided 
on the basis of laboratory testing.  For this reason it may be more prudent, initially, to 
return to the lead compounds themselves as putative agents, given that many – 
methylene blue, crystal violet, acriflavine etc. – possess a considerable history in 
terms of direct human application as anti-infectives.20  Consequently, many such 
examples are covered in this review. 
 
 
5.1. Acridines 
Although as mentioned above, the initial laboratory demonstration of the 
photodynamic effect involved acridine itself [5], in the main, the photosensitising 
activity of this family of compounds has been limited to the early bisamino 
derivatives proflavine and acriflavine.  Much of the associated literature covers 
mutagenic effects in yeast strains as evidence of the deleterious potential of acridine-
based drugs against nucleic acid.21 
 
The acridines represent an important class of agents with respect to the current 
argument.  Several members of this class have been used clinically in a conventional 
antimicrobial capacity, without significant side effects.  Examples include the 
antibacterials aminacrine, proflavine, acriflavine (mixture of proflavine hydrochloride 
and its 10-methyl quaternary salt) and Nitroakridin and the antimalarial agent 
mepacrine (Figure 3).  As mentioned, given the considerable use of these examples as 
drugs, there should be fewer problems with their regulatory approval as clinical 
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photosensitisers than would be the case for completely new agents.  Also as noted 
above, the correlation of DNA binding capability in vitro with 
mutagenicity/carcinogenicity in humans is often an assumed relationship. 
 
 
 
 
 
Figure 3.  Clinically-used antimicrobial acridines. (*10-methyl quaternary salt) 
 
Using the amount of literature concerning nucleic acid interactions of acridines in 
yeasts also as strong evidence for photodynamic activity, photobactericidal 
investigations have been carried out on the effects of a range of structurally-related 
acridines against pathogenic bacteria commonly encountered in the hospital milieu.  
Many of the compounds employed were examples which were, or had been, in use in 
humans as topical antibacterial agents.22 
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  MBC (M)  
 Staphylococcus  aureus Pseudomonas aeruginosa 
Acridine Dark Light* Dark Light* 
Ethacridine 10 5 100 25 
Aminacrine 50 2.5 500 500 
Salacrine 25 2.5 500 500 
Acridine orange 25 1 500 100 
Proflavine 25 2.5 250 10 
 
Table 2  Toxicity and phototoxicity of aminoacridines against bacteria. MBC = 
minimum bactericidal concentration; * fluence rate = 1.7 mW cm-2, fluence = 6.3 J 
cm-2 (white light). 
 
The resulting photobactericidal effects reported were in stark contrast – particularly 
against Gram-positive bacteria (e.g. S. aureus, Table 2) to the related singlet oxygen 
efficiencies of the compounds used in the study, since none of the acridine derivatives 
produced any measurable 1O2 in vitro.
22  Dark toxicities were also measured, at much 
increased concentrations, in agreement with previous work reported to be due to 
bacterial DNA interference via an intercalative mechanism.23  Given this mode of 
action, the increased activity of the acridines used in the study may be considered in 
terms of the disastrous consequences of critically-localised photosensitisers.  In other 
words, bacterial DNA intercalation leads to interference with cellular reproduction, 
but is reversible on removal of the agent; photoactivation of the agent in situ leads to 
oxidation at various points, catastrophic breakdown, and is thus irreversible. 
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Albert and co-workers synthesised many simple amino acridines, which enabled their 
work on the structure-activity relationships of antibacterial examples.24,25  Very few 
have been examined from the photodynamic aspect, so this is another potentially rich 
area for drug discovery. 
 
In terms of drug design, the physicochemical of aminoacridines can be adjusted with 
relative simplicity.  Just as it has been shown that chain length alteration in 10-alkyl 
derivatives of acridine orange leads to differences in mammalian subcellular organelle 
localisation,26 logically the relationship to lipophilicity can also be used to synthesise 
derivatives which do not enter mammalian cells.  For example, the use of quaternising 
chains containing basic character, i.e. as would be protonated in the physiological 
range.  Similar, auxochromic amino substitution having basic functionality has, of 
course, been employed in a great many of the aminoacridines tested for their 
antimalarial potential.27 
 
From a practical point of view, given that such proposed compounds are aimed at 
photodynamic infection control, the aminoacridines generally exhibit their longest 
absorption wavelengths in the 400-500 nm range, so as noted previously, this might 
lead to problems with endogenous absorption.  However, riboflavin (vitamin B2) has 
been reported to retain its photoantimicrobial activity in the presence of red blood 
cells,28 and yet has a strong absorption in this region (475 nm), so it may be that there 
is potential for the aminoacridines here also.  In addition, there is certainly potential 
for their use in infected presentations not involving blood, for example skin or eye 
bacterial or viral disinfection or fungal skin disinfection.  Proflavine was one of the 
photosensitisers employed in the clinical treatment of genital herpes in the 1970s.29 
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It is also possible, should this be required, to extend the absorption of acridine-based 
candidates into the red or near infrared regions.  This is established chemistry,30 and 
utilises the acidic carbon functionality of 9-methyl quaternary acridines to furnish 
styryl derivatives31 (Figure 4).  This has been extended to cyanine-type analogues 
having longer wavelength absorption.32  Little has been reported on the 
photosensitising potential of such derivatives. 
 
 
 
Figure 4.  Acridines with extended spectral absorption.  max values measured in 
methanol.  Typically X = I or Br. 
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5.2. Phenazines 
 
Given the primogenicity of mauveine among synthetic dyes, as a class of compounds 
it is perhaps surprising that the phenazines are not more widely investigated.  Closely 
related to the acridines, several examples of the phenazine class also have the 
capability for DNA intercalation.33,34  The structural commonality is typified by 
neutral red (Figure 5) which, as can be seen from comparison with Figure 4, is 
isosteric with the early clinically-used acridine Flavicid, and also the phenothiazinium 
photosensitiser, toluidine blue (Figure 9). 
 
 
 
 
Figure 5.  Phenazinium dyes 
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DNA-intercalating criteria, i.e. sufficient molecular planar area and cationic charge 
was noted above for the azine class as a whole and unsurprisingly, this interaction has 
been reported for most well-known derivatives (e.g. neutral red35 and 
phenosafranine.36  Most recently, Methylene violet 3RAX (the 7-N,N-diethyl 
analogue of phenosafranine) has also been shown to intercalate strongly with DNA.37 
 
Neutral red is undoubtedly the most commonly tested phenazine in terms of 
photodynamic activity, mainly owing to its involvement in the clinical phototreatment 
of genital herpes in the United States during the late 1960s and early 70s.38  As with 
the simple acridines, neutral red forms aggregated species due to its high degree of 
molecular planarity.  Thus, in terms of singlet oxygen generation, it is important to 
ensure that the correct (monomeric) absorption band is targeted on illumination (max 
monomer = 450 nm; max aggregate = 536 nm).39  However, it should be remembered that 
neutral red is also a live stain for mammalian cells, and this must preclude its use as a 
photoantimicrobial on the grounds of lack of selectivity. 
 
As with other, related azinium-type photosensitisers, the synthesis of neutral red and 
its derivatives is oxidative.  However, derivatives may be prepared easily from a 
nitroso-containing starting material (Figure 6), allowing considerable scope for 
derivatisation, for example altering the hydrophilic/lipophilic balance of the molecule 
via hydroxylation of the auxochromic alkyl groups.40 
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Figure 6.  Classical synthesis of phenazinium dyes showing facile variation.  
Typically R is an alkyl group. 
 
Safranine O was one of the early biological stains to be demonstrated as a Gram-
negative photobactericide, a logical use given its part in the Gram-staining 
procedure.41  Interestingly, more recently it has also been patented for 
photoantimicrobial use.42 
 
Novel photosensitiser geometries might also be achieved by facile alteration of the 
azoaryl moiety in Janus green (Figure 5), given that this molecule arises merely from 
the coupling of diazotised methylene violet 3RAX and N,N-dimethylaniline.  Again 
this would allow for alteration of physicochemical properties.  As with neutral red, 
Janus green is taken up by mammalian cells, thus a significant increase in the 
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hydrophilicity of the molecule would be required in order for microbial selectivity to 
be achieved. 
Janus green is unusual among the phenazinium dyes for its long wavelength 
absorption.  For the most part established phenazinium compounds have associated 
max values short of the therapeutic window normally expected for photoantimicrobial 
applications.  This has been remedied via both extension of the chromophore and 
rigidification of the amine auxochromic groups, through the use of N,N-
dialkyltetrahydroquinoxaline as a starting material.  The resulting pentacyclic 
phenaziniums exhibited both increased max values and singlet oxygen yields (Figure 
7).43 
 
 
 
Figure 7.  Increased wavelength and singlet oxygen quantum yield in rigidified 
phenazinium derivatives 
 
 
5.3. Phenoxazines 
 
Clinical interest in this class comes from long experience with the biological stain 
Nile blue A.  This is, in fact a benzo[a]phenoxazine (Figure 8), and it is thus dealt 
with under Benzannelated Compounds, below.  Basic blue 3 (Figure 8) is the best 
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known example of the phenoxazinium class itself but is of no use in terms of the 
photodynamic effect. 
 
 
 
Figure 8.  Phenoxazinum derivatives 
 
The phenoxazine dyes, i.e. oxygen analogues of the methylene blue-type 
phenothiaziniums, do not produce reactive oxygen species on illumination, whether 
by a Type I or Type II mechanism.  The excited state is very short-lived in the parent, 
undeveloped phenoxazinium chromophore.  However, extended lifetimes can be 
realised via the use of the heavy atom effect, i.e. the inclusion of low-period atoms in 
the structure which stabilise the excited state molecule, as has been carried out for the 
realisation of effective Nile blue derivatives (below). 
 
Due to the instability of the excited state chromophore, phenoxazinium dyes find 
considerable use as fluorescent sensors44.and, in line with previous work on Nile blue, 
have also been suggested as conventional antimalarial leads (e.g. Figure 8).45 
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5.4. Phenothiazines 
 
 
 
Figure 9.  Phenothiazinium photoantimicrobial leads 
 
Given the longevity of the medical use of methylene blue (MB, Figure 9), it is 
surprising that there has not been more drug development based on this structure.  As 
noted earlier, MB has found use in a variety of roles, in addition to its position as lead 
compound in antimalarial, antipsychotic and antidepressant research.9  However, its 
primogenicity in matters photoantimicrobial has probably inhibited the further clinical 
introduction of newer phenothiazinium photosensitisers, particularly from a 
toxicology point of view: MB is safe for human use, whereas any new chemical entity 
based on its structure would have to undergo extensive testing prior even to pre-
clinical trialling.  There are many examples of new compounds based on MB which 
have far greater photoantimicrobial potential – MB itself is only a moderate example 
– but these face huge regulatory barriers, whereas MB is already licensed for use in 
blood product photodecontamination,46 and oral and nasal photodisinfection.47 
 
As far as drug development is concerned, the synthesis of novel phenothiaziniums has 
seen higher productivity than even the benzo[a]phenoxazinium (Nile blue) 
derivatives.  In addition, there exists a greater mix of peripheral and auxochromic 
congeners among MB derivative series. 
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Synthesis 
The traditional, dye industry, synthesis of MB utilises the oxidative coupling of N,N-
dimethylaniline and N,N-dimethyl-p-phenylenediaminethiosulphonic acid which is 
produced in situ.  The coupled intermediate, Binschedler’s green is oxidatively 
cyclised to provide the phenothiazinium chromophore (Figure 10). 
In terms of analogue production for drug design, this is an unsuitable process, 
principally because of the strong oxidants, e.g. chromium(VI), utilised during the 
synthesis which cause denaturation of auxochromic groups and peripheral 
substituents.  Similarly, the traditional synthesis is carried out in aqueous media, 
which limits the lipophilicity of starting materials and products alike. 
 
 
 
Figure 10.  ‘Classical’ thiosulphonic acid synthesis of methylene blue derivatives.  R 
is typically alkyl or aryl. 
 
Weaker oxidants, such as silver(I) salts in alcoholic media, allow greater product 
range via a similar route to that described above, while the use of iodine or bromine 
provides a straightforward method of preparation of direct methylene blue analogues 
(Figure 11).48 
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Figure 11.  Symmetrical and asymmetrical phenothiazinium/chalcogen analogue 
formation from the reduced parent (R = alkyl or aryl; X = S, Se) 
 
Despite such advances in synthetic methodology, the preponderance of novel 
derivatives is of the direct methylene blue type – i.e. auxochromic variants only 
(Figure 12).  Few workers have reported chromophoric substitution of lead 
compounds, thus limiting proper drug discovery.  However, a range of chromophore 
methylated derivatives49 and a homologous series based on a second lead, toluidine 
blue (Figure 9), have been reported.50  Similarly, the use of indoline and 
tetrahydroquinoline precursors has allowed the synthesis of tetra- and pentacyclic 
derivatives (Figure 12).51,52 
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Figure 12.  Phenothiazinium photoantimicrobial variants.  R, R’ = alkyl, aryl. 
 
Activities 
Generally, most series based on MB have contained analogues with significantly 
greater photoantimicrobial activities than the parent.  Such increases have not been 
correlated to singlet oxygen yields, which is not surprising given that – as noted above 
– singlet oxygen measurement in vitro and cell killing in culture are two very different 
processes, the latter including cellular uptake and potential metabolism of the 
photosensitiser, neither of which is related to singlet oxygen yield. 
 
A good example of this phenomena is provided by the pentacyclic derivative DO15 
(S137).  This produces lower yields of singlet oxygen than MB, but is considerably 
more active as a photoantimicrobial under the same conditions as the parent (Table 
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3).52  In addition, its activity against Gram-negative bacteria is greater than usually 
seen with phenothiazinium photosensitisers and this is due to its lower propensity to 
aggregate formation (due to bulkier molecular shape) and ability to alter membrane 
structure.53 
 
 
 
     MBC  (M)  
    S.  aureus E. coli 
Ps max (nm) Log P Rel. 1O2 Light* Dark Light* Dark 
MB 660 -0.10 1.00 25 100 25 50 
1 664 +0.80 0.55 6.25 100 6.25 100 
2 678 +1.44 0.87 3.13 100 3.13 100 
137 683 +1.54 0.92 0.78 100 3.13 100 
 
Table 3.  Properties and photoactivities of a series of methylene blue derivatives.  * 
fluence rate = 100 mW cm-2, fluence = 6.2 J cm-2 (red light) 
 
 
5.5. Phenoselenazines 
As noted under Phenoxazines, the heavy atom effect has been utilised in several 
photosensitiser types in order to increase the occurrence of inter-system crossing and 
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significant production of the activated photosensitiser triplet state.  Given that the 
change from ring oxygen to ring sulphur (phenoxazinium to phenothiazinium 
chromophore) generally furnished efficient photosensitisers via this route, the 
subsequent change to ring selenium should be supposed to provide further increases in 
singlet oxygen yields.  Very little work has been carried out following this line of 
inquiry, compared to the benzologues or rosamine derivatives (q.v.). 
However, a series of selenium homologues of MB was synthesised and tested by 
Griffiths and Gorman, with surprising results from both in vitro and 
photoantimicrobial testing Table 4.54 
 
Synthesis of the derivatives followed the earlier halogen oxidation work on 
phenothiazine (Figure 11), but using 10H-phenoselenazine instead as the starting 
material. 
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X = Se54 
 max   10 M Log Photokill
† 
R (nm, H2O) LogP Relative S. aureus E. coli 
Me (MB) 660 -0.10 1.00 - - 
Et 664 +1.50 1.50 1.74 3.33 
n-Pr 670 >+2 1.11 1.70 3.16 
n-Bu 670 >+2 0.92 2.72 3.78 
 
X = S13 
 
 max   6-Log Photokill (M)* 
R (nm, H2O) LogP Relative S. aureus E. coli 
Me (MB) 660 -0.10 1.00 25 25 
Et 664 +0.81 0.55 6.3 6.3 
n-Pr 669 +1.10 0.59 3.1 6.3 
n-Bu 671 +1.34 0.61 3.1 3.1 
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Table 4. Properties and photobactericidal activities of MBDs and selenologues.  † 
Fluence rate = 10 mW cm-2, fluence = 3.0 J cm-2 (red light)*Fluence rate = 10 mW 
cm-2, fluence = 6.2 J cm-2 (red light) 
 
 
5.6. Benzannelated Compounds 
 
The selectivity of the benzo[a]phenoxazine Nile blue for tumour tissue in vivo during 
the mid-20th Century led to the use of this as a lead compound for anticancer PDT 
agents by Foley in the 1980s.55  Interestingly, a significant series of papers by 
Crossley et al. concerning Nile blue derivatives (NBDs) as potential anti-tubercular 
agents was published in the 1950s.  Although photodynamic testing was not carried 
out in either the tumour staining or anti-TB work, the biological activity demonstrated 
in both cases is a strong argument for drug development and photodynamic analogues 
have resulted.56 
 
As with the phenoxazinium parent chromophore, the disadvantage of Nile blue lies in 
its lack of photodynamic activity, whether by a Type I or Type II mechanism. 
Similarly bromo- and iodo-analogues have been synthesised with increased yields of 
singlet oxygen, but perhaps more significantly ring analogues with sulphur or 
selenium replacing oxygen have provided excellent scaffolds for drug development in 
the area of photoantimicrobials.  As can be seen from Figure 13, the influence of 
heavy atoms is considerable. 
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Figure 13.  Chalcogen substituted photosensitisers 
 
Due to its relatively high yield of singlet oxygen, the benzo[a]phenoselenazinium 
derivative EtNBSe (X = Se, Figure 13) has been used by several groups to investigate 
applications in photoantimicrobial activity as well as further synthesis.57 
 
In terms of functionalisation, and as with most of the derivatives discussed in this 
review, very little has been reported concerning peripheral substitution.  Clearly it is 
much simpler to produce analogues having variation in the auxochromic group, given 
the wide variety of amines available, but also due to the alteration of the redox 
characteristics of the parent aromatic constituents on functionalisation, which often 
inhibits either aromatic coupling in (A+B)-type syntheses, or chromophoric oxidation 
to yield the cationic heteroaromatic system. 
 
Within this area, the effect of charge on the photobactericidal acitivity (as noted above 
for the anionic porphyrins) has been reported for the sulphur analogue (Figure 13, X = 
S).  As expected, the presence of an anionic carboxylate residue removed activity 
against the Gram-negative bacterium Escherichia coli.58  Unsurprisingly, also, the 
inclusion of a (cationic) guanidinyl moiety on the N-ethyl side chain has been found 
to increase photobactericidal activity against Gram-negative species, including the 
dangerous pathogen Acinetobacter baumanii.59 
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5.7. Xanthyliums (Rosamine-type) 
 
While rhodamines have exhibited reported activity in the field of PDT, as noted 
above, this is not necessarily an indication of potential for photoantimicrobial action, 
and certainly the propensity for rhodamine uptake by mammalian mitochondria60 
would argue against the selectivity of such examples for microbial cells.  However, 
the structurally related pyronines – i.e. rhodamines without the 9-aryl moiety are 
singlet oxygen producers and highly active photobactericides.61  Given the anionic 
contribution of the 2’-carboxyl function in rhodamines, broad-spectrum activity 
against microbial species is unlikely, thus the removal of this group to furnish the 
cationic rosamines is logical.  This class of photosensitiser might therefore be thought 
of as a 9-arylpyronine or, conversely, a 2,2’-oxygen-bridged triarylmethane.  Either 
scenario provides antimicrobial pedigree. 
 
In relatively recent work by Detty et al., rosamine derivatives containing bridging 
heteroatoms other than oxygen were reported to have associated singlet oxygen yields 
similar to those of the phenothiaziniums, once again demonstrating the importance in 
photosensitiser design of the heavy atom effect (Figure 14). 
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Figure 14. Pyronin and simple rosamine derivatives 
 
Rosamine analogue synthesis is relatively straightforward62 and a variety of 9-
aryl/heteroaryl substituents may be obtained via organometallic attack on the 
corresponding xanthone derivative (Figure 15). 
 
 
 
Figure 15.  Synthesis of functionalised sulphur and selenium rosamine analogues (X = 
S, Se, Ar = aryl or heteroaryl nucleus) 
 
For example, the use of 2-lithiothiophene produces the 9-thienoanalogue,63.which 
extends the longest absorption  wavelength to 590 nm (methanol) for the thiorosamine 
analogue, compared to 571 nm for the equivalent 9-phenyl derivative. 
 
 
 
Figure 16.  9-(2’-Thienyl)- and auxochrome-rigidified rosamine derivatives (X = S, 
Se). 
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Rigidification of one of the amino auxochromes (e.g. the julolidino derivative, Figure 
16, max = 582 nm) has a lesser effect on wavelength.64  As expected, the heavy atom 
effect also produces longer wavelengths, but the use of structural alterations other 
than that of heavy atom substitution does not appear to alter the singlet oxygen yield 
significantly. 
 
Tellurium substitution is, of course the rational extension of this work - although there 
remain some concerns about the associated potential toxicity of this element - and this 
has been achieved, in contrast to work carried out in the study of phenothiazinium and 
benzo[a]phenothiazinium photosensitiser analogues.  Tellurium-containing analogues 
have been synthesised which show the expected extension of the absorption spectrum 
beyond 600 nm.65  Effects of the heavier atoms on max for the 9-(2-thienyl) 
compound can be seen in Figure 17. 
 
 
 
Figure 17.  Effect of lower period atom inclusion in rosamine derivatives. 
 
Apart from derivatives intended for use in blood photodecontamination (e.g. the 9-
thienyl seleno-derivative mentioned above), the majority have been aimed at PDT 
application.  Consequently, this is an area worth exploring for novel 
photoantimicrobial derivatives.  However, it is noticeable that the wavelength range of 
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derivatives reported thus far has been significantly shorter than that normally desired 
for anti-infective work, as noted above (Photosensitiser Requirements). 
 
 
6. Future directions 
 
In the early 21st Century, the photoantimicrobial approach has not yet reached proper 
clinical acceptance, being largely ignored by the pharmaceutical industry and viewed 
mainly sceptically by the medical profession in most countries.  Consequently, to 
discuss novel derivatives at such a stage of development might seem somewhat 
fanciful. 
 
This is not the case, due to the ever-increasing problem of clinical drug resistance 
among many serious pathogens and the very slow production of new antimicrobials.  
The ‘treatment gap’ in hospitals worldwide is becoming greater year on year and new 
approaches, hopefully including photoantimicrobials, must be employed in order at 
least to slow resistance development.  The local application of photoantimicrobials 
offers considerable potential for the conservation of traditional antimicrobial drugs. 
 
The few instances of current clinical photoantimicrobial use, whether in oral or nasal 
disinfection or in blood product photodecontamination employ methylene blue for the 
most part.  It is hoped that this use will extend in these areas and that others in 
infection control will be developed.  Novel photoantimicrobials will be required at 
this stage on the grounds of efficacy in the different presentations, but also for the 
commercialisation of the product, in the same way as conventional antimicrobials. 
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Given the very close similarities between the various derivatives discussed here, it is 
possible to derive a general structure-activity picture, as shown in Figure 18. 
 
 
 
Figure 18.  Structure-photophysical relationships in cationic, azine-type 
photosensitisers 
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